glp-1 drugs key developments 2025 Weight Loss Drugs: How Semaglutide & Tirzepatide Redefine Obesity Care Patients Face New Barriers for

The commonly observed increase in GLP-1 after bariatric surgery [[211], [212], [213], [214], [215], [216]] is considered a causal factor leading to increased circulating levels of insulin after the surgery

These developments will have implications for numerous stakeholders within the industry

Not only is it important to know all the beneficial effects, but it also is important to know the potential negative effects, so patients can be counseled properly. The next steps would be to design a study to see the mechanism for improvement in cardiovascular health, he added

If approved, the expanded indications will not only increase utilization for those conditions, they may also give manufacturers greater access to more of the obesity market, he says, as many of these conditions are considered comorbidities of diabetes and obesity

What are the real risks to know about

Most of these patients had a decrease in the indices of liver fibrosis and inflammation, but they also showed elevated levels of LDL-C, insulin, and a decrease in HDL-C